Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects

Journal of Clinical Pharmacology

Volumn 48, Issue 8, 2008, Pages 948-956

  Ji, Ping ^a,e   Damle, Bharat ^a,b   Xie, Jingdong ^a,c   Unger, Steve E ^a,d   Grasela, Dennis M ^a   Kaul, Sanjeev ^a  

^a BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^b Pf Izer Global Research and Development   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d Wyeth   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Carbamazepine; Drug interaction; Efavirenz; Pharmacokinetics

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLOZAPINE; EFAVIRENZ; PHENYTOIN; RIFAMPICIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG METABOLISM; EVENING DOSAGE; FEMALE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NEUTROPENIA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-HIV AGENTS; ANTICONVULSANTS; AREA UNDER CURVE; BENZOXAZINES; BIOTRANSFORMATION; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; SAMPLE SIZE;

EID: 47549099207     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008319792     Document Type: Article

References (39)

1. Levy RM, Bredesen DE, Rosenblum ML, Davis RL Central nervous system disorders in AIDS. Immunol Ser. 1989 ; 44: 371-401.
2. Pascual-Sedano B., Iranzo A., Marti-Fabregas J., et al. Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. Arch Neurol. 1999 ; 56: 609-612.
3. Sustiva (efavirenz) tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Co ; April 2005.
4. Canavero S., Bonicalzi V. Drug therapy of trigeminal neuralgia. Expert Rev Neurother. 2006 ; 6: 429-440.
5. Mateu-de Antonio J., Grau S., Gimeno-Bayon JL, Carmona A. Ritonavir-induced carbamazepine toxicity. Ann Pharmacother. 2001 ; 35: 125-126.
6. Bertilsson L., Hojer B., Tybring G., Osterloh J., Rane A. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther. 1980 ; 27: 83-88.
7. Laroudie C., Salazar DE, Cosson JP, et al. Carbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol. 2000 ; 20: 46-53.
8. Villikka K., Kivisto KT, Maenpaa H., Joensuu H., Neuvonen PJ Cytochrome P450-inducting antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 1999 ; 66: 589-593.
9. Baciewicz AM Carbamazepine drug interactions. Ther Drug Monit. 1986 ; 8: 305-317.
10. Liedtke MD, Lockhart SM, Rathbun RC Anticonvulsant and antiretroviral interactions. Ann Pharmacother. 2004 ; 38: 482-489.
11. Gibaldi M., Perrier D. Non-compartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D, eds. Pharmacokinetics. 2 nd ed. New York: Marcel Dekker ; 1982: 409-418.
12. Diletti E., Hauschke D., Steinijans VW Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 ; 29: 1-8.
13. Statistical Analysis Systems (SAS). Version 8.2. Cary, NC: SAS Institute, Inc ; 1999.
14. Arroyo S., Sander Jwas. Carbamazepine in comparative trials. Am Acad Neurol. 1999 ; 53: 1170-1174.
15. Adkins JC, Noble S. Efavirenz. Drugs. 1998 ; 56: 1055-1064.
16. McNamara PJ, Colburn WA, Gibaldi M. Time course of carbamazepine self-induction. J Pharmacokinet Bipharm. 1979 ; 7: 63-68.
17. Benedek IH, Joshi A., Fiske WD, et al. Pharmacokinetic interaction between efavirenz (efavirenz) and rifampin (RIF) in healthy volunteers. Presented at: 12th World AIDS Conference ; June 28 to July 3, 1998 ; Geneva, Switzerland. Abstract 42280.
18. Lopez-Cortez LF, Ruiz-Valderas R., Viciana P., et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002 ; 41: 681-690.
19. Piscitelli SC, Gallicano KD Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001 ; 344: 984-996.
20. European Agency for the Evaluation of Medicinal Products. Efavirenz (Sustiva®): summary of product characteristics. Available at: http://www.eudra.org/humandocshumans/epar/sustiva/sustiva.htm.
21. Centers for Disease Control and Prevention (CDC). Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep. 2000 ; 49: 185-189.
22. National Institutes of Health (NIH). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://AIDSinfo.nih.gov.
23. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000 ; 30: S151 - S159.
24. Marzolini C., Telenti A., Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001 ; 15: 71-75.
25. Veldkamp AI, Hoetelmans RMW, Beijnen JH, et al. High exposure to nevirapine is associated with a high initial HIV-1 clearance rate, a higher likelihood to reach indetectability and prolonged suppression of HIV-1 replication. Presented at: Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection ; October 23-27, 1999 ; Lisbon, Portugal. Abstract 239.
26. Störmer E., von Moltke LL, Perloff MD, Greenblatt DJ Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res. 2002 ; 19: 1038-1045.
27. Tsuchiya K., Gatanaga H., Tachikawa N., et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004 ; 319: 1322-1326.
28. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003 ; 306: 287-300.
29. Yamano S., Nhamburo PT, Aoyama T., et al. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry. 1989 ; 28: 7340-7248.
30. Ekins S., Vandenbranden M., Ring BJ, et al. Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 ; 286: 1253-1259.
31. Hass D., Ribaudo H., Kim R., et al. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects. AACTG Study NWC5214. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004 ; San Francisco, CA. Abstract 133.
32. Tybring G., von Bahr C., Bertilsson L., Collste H., Glaumann H., Solbrand M. Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metab Dispos. 1981 ; 9: 561-564.
33. Tegretol (carbamazepine) tablets, suspension, and extended release tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation ; 2000.
34. Strandjord RE, Johannessen SI Single-drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effects. Epilepsia. 1980 ; 21: 655-662.
35. Schmidt D., Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in seizure frequency and type. Neurology. 1984 ; 34: 1252-1255.
36. Callaghan N., Kenny RA, O'Neill B., Crowley M., Goggin T. A prospective study between carbamazepine, phenytoin, and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry. 1985 ; 48: 639-644.
37. Herranz JL, Armijo JA, Arteaga R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia. 1988 ; 29: 794-804.
38. Riva R., Albani F., Contin M., Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacokinet. 1996 ; 31: 470-493.
39. Treston AM, Hooper WD Urinary metabolites of phenobarbitone, primidone, and their N-methyl and N-ethyl derivatives in humans. Xenobiotica 1992 ; 22: 385-394.